VLA-5: A Potential Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

Target Name: Integrin alpha5beta1 (VLA-5) receptor

NCBI ID: P5762

Integrin alpha5beta1 (VLA-5) receptor

Other Name(s): None

VLA-5: A Potential Drug Target for Cancer, Neurodegenerative Disorders and Autoimmune Diseases

Integrin alpha5beta1 (VLA-5) receptor, also known as CD73, is a transmembrane protein that plays a crucial role in cell-cell adhesion and tissue regeneration. It is expressed in various tissues, including the skin, hair, nails, and heart, and is involved in the regulation of cell growth, differentiation, and survival.

Recent studies have identified VLA-5 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its role in these conditions makes it an attractive target for researchers to explore new therapeutic approaches.

One of the key reasons for the interest in VLA-5 is its involvement in cancer progression. VLA-5 has been shown to promote the growth and survival of cancer cells, and it has been identified as a potential therapeutic target for various cancers. For example, a study by Kim et al. (2014) found that inhibition of VLA-5 reduced the migration and invasion of cancer cells. Another study by Zhang et al. (2019) found that overexpression of VLA-5 led to the formation of cancer stem cells, which are responsible for the development and progression of cancer.

In addition to its role in cancer, VLA-5 has also been linked to neurodegenerative disorders. VLA-5 has been shown to participate in the regulation of neuronal excitability and synaptic plasticity, which are important for the functioning of the nervous system. A study by Chen et al. (2014) found that VLA-5 was involved in the regulation of synaptic plasticity in the brain, and that its overexpression led to the formation of neurodegenerate plaques.

Another potential application of VLA-5 is its role in autoimmune diseases. VLA-5 has been shown to contribute to the development and progression of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. A study by Wang et al. (2018) found that VLA-5 was involved in the regulation of immune cell function and that its overexpression led to the development of autoimmune disease.

Despite the potential benefits of VLA-5 as a drug target, there are also concerns about its safety and potential side effects. VLA-5 has been shown to be involved in various physiological processes, including cell adhesion, migration, and invasion, which could make it a potential hazard in some diseases. A study by Lin et al. (2014) found that VLA-5 was involved in the regulation of blood vessel growth and that its overexpression led to the formation of blood vessels in the skin.

In conclusion, VLA-5 is a transmembrane protein that plays a crucial role in cell-cell adhesion and tissue regeneration. Its involvement in cancer, neurodegenerative disorders, and autoimmune diseases makes it an attractive target for researchers to explore new therapeutic approaches. While there are also concerns about its safety and potential side effects, the potential benefits of VLA-5 make it a valuable tool for the development of new treatments.

Protein Name: Integrin Alpha5beta1 (VLA-5) Receptor

The "Integrin alpha5beta1 (VLA-5) receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alpha5beta1 (VLA-5) receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets